RxDoctor Payments Data

Marylynn Parker, MD

Family Medicine · Dothan, ALNPI 1780651711

Payments from drug & device makers

$3,788in general payments, 2019–2025

Across 247 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$619
  • Novo Nordisk$487
  • GSK$459
  • AbbVie$287
  • Lilly USA, LLC$286
  • E.r. Squibb & Sons, L.L.C.$245
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,69498%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,788 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$46,127
Medicare patients
91
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$102,036
JanuviaSitagliptin Phosphate64$95,569
MounjaroTirzepatide66$89,481
EliquisApixaban50$61,979
RybelsusSemaglutide22$50,888
FarxigaDapagliflozin Propanediol35$46,803
TrulicityDulaglutide39$45,369
JardianceEmpagliflozin27$40,680
MyrbetriqMirabegron44$32,460
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,947
Colesevelam Hcl74$14,432
LinzessLinaclotide11$12,652
VascepaIcosapent Ethyl16$12,274
Breo ElliptaFluticasone/Vilanterol21$11,787
Dexlansoprazole DrDexlansoprazole38$10,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$487$152,92488 claims
Lilly USA, LLCMounjaro, Trulicity$286$134,850105 claims
MerckJanuvia$97$95,56964 claims
PfizerEliquis$121$61,97950 claims
AstraZenecaFarxiga$194$46,80335 claims
Boehringer IngelheimJardiance$131$40,68027 claims
Astellas Pharma US IncMyrbetriq$619$32,46044 claims
GSKTrelegy Ellipta, Breo Ellipta$459$29,73349 claims
AbbVieLinzess, Synthroid$287$15,10028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →